Trial watch

摘要

Patients with non-small-cell lung cancer (NSCLC) can receive various chemotherapy treatments, but how should their drug regimen be selected? Patients with mutations in their epidermal growth factor receptor (EGFR) respond better to the EGFR inhibitors erlotinib and gefitinib than patients without these mutations, and patients with NSCLC that overexpresses BRCA1 are usually resistant to cisplatin. Rafael Rosell and colleagues conducted a prospective, non-randomized Phase II clinical trial to investigate whether using these biomarkers to determine the therapy patients with NSCLC receive can improve survival rates compared with non-personalized therapy.